Adamis Pharmaceuticals Corporation (ADMP)

0.7750 +0.0065 (+0.85%) At close: 03:59PM EDT

Adamis Pharmaceuticals Corporation

11682 El Camino Real
Suite 300
San Diego, CA 92130
United States
858 997 2400
https://www.adamispharmaceuticals.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 11

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David J. Marguglio	Co-Founder, Interim CFO. Pres & COO	526.35k	N/A	1970
Dr. Ebrahim Versi M.D., Ph.D.	CEO & Chair of the Board	N/A	N/A	1953
Ms. Jennifer C. Suski	Sr. Director of Marketing	N/A	N/A	N/A
Mr. Eddie Wabern Glover	Chief Exec. Officer of US Compounding Inc	N/A	N/A	1950
Mr. Robert B. Rothermel	Consultant	N/A	N/A	1944

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Corporate governance

Adamis Pharmaceuticals Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.